(VEEV) Veeva Systems Inc. Company Overview

What does Veeva Systems do?

Veeva Systems Inc. is a New York Stock Exchange-listed software company under ticker VEEV that builds an industry cloud for life sciences. In practical terms, it supplies pharmaceutical, biotechnology, and medical-technology companies with software, artificial intelligence, data, and consulting used from clinical development through commercial launch. Its systems manage regulated documents, clinical trial data, safety cases, quality processes, customer relationships, marketing content, and healthcare-professional data. That end-to-end scope makes Veeva more than a narrow software vendor: it is increasingly an operating layer for critical workflows where data integrity, validation, privacy, and regulatory compliance matter.

Which product clouds define the company?

For financial reporting, those four clouds collapse into two product areas: Commercial Solutions, which combines Commercial Cloud and Data Cloud, and R&D and Quality Solutions, which combines Development Cloud and Quality Cloud. This distinction is important because R&D and Quality has become the larger revenue area, while the CRM transition and the addition of AI are reshaping Commercial Solutions.

How does Veeva make money, and which product area matters most?

Veeva earns most of its revenue from customers paying recurring fees to access software and data products. Subscription revenue is recognized over the contract term and benefits from renewals, additional users, new applications, greater data usage, and expansion into more business functions. Professional services and other revenue comes mainly from implementation, configuration, managed services, consulting, and related activities. The service work helps customers deploy complex systems, but it carries much lower gross margins than the subscription layer.

What is the revenue mix?

The key mix shift is toward R&D and Quality Solutions. That area represented 55% of FY2026 total revenue and again 55% in the first quarter of FY2027. It benefits from broad product depth across clinical, regulatory, safety, quality, and manufacturing workflows. Commercial Solutions remains strategically important because Vault CRM, Data Cloud, Crossix analytics, and agentic commercial products connect Veeva to customer-facing activity and data. The business-model tension is therefore clear: Veeva must protect and rebuild its CRM position while continuing to compound the larger R&D and Quality franchise.

What does Veeva’s latest quarter show?

The latest official period is the first quarter of fiscal 2027, ended April 30, 2026. Veeva reported broad-based growth, higher GAAP operating income, and a very strong seasonal cash inflow. Management also raised full-year guidance. The freshest figures are available in the company’s fiscal 2027 first-quarter release and the corresponding Form 10-Q.

What changed in profitability and product mix?

Management guided Q2 FY2027 revenue to $902M-$905M and raised FY2027 revenue guidance to $3.635B-$3.645B, with non-GAAP operating income of about $1.610B. Guidance is not a guarantee, but it frames the near-term model: mid-teens top-line growth, continued profitability, and substantial spending on AI, product development, customer migrations, and acquisitions.

Which turning points shaped Veeva’s strategy?

Veeva’s history is best understood as a sequence of scope expansions. It began by solving one life-sciences-specific commercial problem, then built a proprietary platform and extended into development, quality, data, and now agentic AI. Each step increased the number of regulated workflows in which Veeva could become embedded.

1. 2007
   Veeva was founded around a vertical-cloud thesis: life sciences needed purpose-built software rather than generic enterprise applications. That narrow focus created domain expertise and an initial CRM beachhead.
2. 2011-2013
   Veeva Vault broadened the company beyond CRM into regulated content and data management. The October 2013 IPO supplied public-market capital and credibility while the company was already profitable.
3. 2016-2018
   Clinical, regulatory, quality, safety, and analytics applications expanded Vault into suites. This shifted Veeva from a commercial software specialist toward an industry operating platform.
4. 2019
   The $430M cash acquisition of Crossix added privacy-safe patient data and analytics, strengthening commercial measurement and creating a major Data Cloud building block. The transaction is documented in Veeva’s official acquisition announcement.
5. 2021
   Veeva converted to a Delaware Public Benefit Corporation. The legal structure formalized a long-term stakeholder orientation and requires directors to balance shareholder economics, materially affected stakeholders, and the company’s public benefit purpose.
6. 2022-2025
   Veeva committed to moving CRM from Salesforce’s platform to its own Vault platform. The Salesforce agreement entered a wind-down on September 1, 2025, making customer migration and competitive retention a defining execution test through 2030.
7. 2025-2026
   Veeva launched its industry AI initiative, acquired Ostro for compliant conversational engagement, and acquired Copli to launch Falcon MLR. The June 2026 Copli and Falcon MLR announcement shows the strategy moving from embedded AI features toward agentic labor.

The most consequential turning point is the CRM platform transition. It removes long-term dependence on Salesforce and could improve product integration, control, and economics. Yet it also creates a period in which customers must choose between migrating to Vault CRM or selecting Salesforce’s industry CRM. That makes the transition both a moat-building investment and a source of churn risk.

Why are Vault, vertical focus, and regulated workflows a competitive advantage?

Veeva’s moat is not simply “software for pharma.” It comes from combining industry specialization with a platform that manages content, data, workflows, and increasingly AI agents under demanding compliance requirements. A generic software provider can offer broad technology, but Veeva packages life-sciences terminology, data models, validation practices, regulatory functionality, and workflow logic into standard products. That can shorten implementation, reduce customization, and make upgrades more repeatable.

Where do switching costs come from?

Switching costs arise because these systems hold regulated records, connect multiple departments, and must be validated. Replacing a clinical, regulatory, quality, or safety platform can require data migration, process redesign, retraining, integrations, validation, and governance approvals. Once a customer runs several applications on Vault, the shared data model and cross-functional workflows can deepen the cost and risk of moving away.

How does Veeva AI reinforce the platform thesis?

Veeva is adding agents directly to applications rather than positioning AI as a separate general-purpose toolkit. Its official Veeva AI description emphasizes secure access to application data, documents, and workflows. The strategic advantage is contextual access: an agent operating inside a validated application can use the company’s permissions, process state, data model, and approved content. If customers trust the controls, AI may increase product usage and raise the value of having data and workflow on one platform.

Who competes with Veeva during the Vault CRM transition?

Competition differs by product. Salesforce is the primary CRM competitor and is especially important because Veeva’s legacy CRM ran on Salesforce’s platform. IQVIA competes in life-sciences data and analytics; Oracle, Dassault Systèmes, OpenText, Honeywell, Microsoft, Box, and smaller specialists compete in parts of development, quality, content, and platform functionality. Customers can also build internal systems or use broad cloud services. Veeva’s fiscal 2026 Form 10-K explicitly notes that no single vendor competes with every Development Cloud or Quality Cloud application.

Why is the Salesforce wind-down strategically unusual?

This is not a routine product upgrade. It asks customers to make a platform decision while Salesforce actively markets a competing life-sciences CRM. Success would give Veeva greater control over architecture, release cadence, economics, and AI integration. Failure would weaken Commercial Solutions growth and could reduce cross-selling into Data Cloud and commercial content. Researchers should therefore treat Vault CRM customer additions, go-lives, migrations, and losses as core strategic KPIs, not product-launch trivia.

How financially strong is Veeva?

Veeva combines high subscription gross margins, meaningful GAAP profitability, strong operating cash generation, and an unusually liquid balance sheet. At April 30, 2026, cash and short-term investments totaled $7.3B, compared with total liabilities of $1.83B and stockholders’ equity of $7.30B. The company does not report conventional funded debt in its latest balance sheet; lease liabilities and operating obligations are much smaller than its liquid asset base.

What do margins and cash conversion say?

How is capital being allocated?

Capital allocation has broadened. Veeva still prioritizes internal product investment, but it has also used acquisitions to add data and AI capabilities and began a $2B repurchase program in January 2026. By April 30, 2026, it had repurchased 1.255M shares during the quarter at an average price of $176.17, and $1.599B remained authorized. Veeva does not expect to pay a cash dividend for the foreseeable future. For valuation work, repurchases should be assessed against dilution from employee equity, acquisition opportunities, and the opportunity cost of deploying a large cash balance.

Who owns Veeva stock, and how is the company governed?

Veeva now has a single class of common stock with one vote per share, so economic ownership and voting power are generally aligned. Founder and CEO Peter Gassner remains the most influential individual shareholder, while institutional ownership is dispersed. The latest official ownership table appears in Veeva’s 2026 proxy statement, using March 31, 2026 ownership data.

Why does Public Benefit Corporation status matter?

The PBC structure does not make Veeva a nonprofit. It remains a for-profit corporation, but directors must balance shareholder financial interests, the interests of stakeholders materially affected by the company, and Veeva’s stated public benefit purpose. The company’s vision is to build the industry cloud for life sciences, and its values are ordered as “Do the Right Thing,” customer success, employee success, and speed. This can support long-term customer trust in regulated markets, but it also gives the board wider latitude when stakeholder interests conflict with near-term shareholder preferences.

What governance signals should investors note?

The board stated that every director except Gassner was independent under NYSE standards for the 2026 proxy cycle. Veeva has a declassified board, a single share class, proxy access, a process for shareholders to call special meetings, and a standing cybersecurity committee that also oversees AI compliance risk. Shareholder engagement reached holders representing about 40% of shares outstanding, with meetings covering about 30%. These are important counterweights to founder influence and the discretion inherent in PBC status.

What opportunities and risks could change Veeva’s outlook?

The opportunity set is large because life-sciences companies still operate fragmented systems across clinical development, regulatory submissions, safety, manufacturing quality, commercial engagement, and data. Veeva can grow by selling more applications to existing customers, migrating CRM users to Vault, expanding Data Cloud, applying AI to high-cost regulated labor, and extending selected quality products beyond life sciences. Its balance sheet also gives it flexibility to acquire specialized capabilities without depending on external financing.

Which risks are most company-specific?

Which KPIs and valuation drivers matter most for Veeva?

A Veeva valuation should not be built from revenue growth alone. The key variables are subscription growth, product-area mix, GAAP and cash margins, reinvestment, dilution, CRM retention, and the durability of the company’s competitive position. Veeva’s huge cash portfolio also requires care: enterprise value should separate operating performance from excess liquidity, while interest income should not be treated as permanent operating profit.

How should a student frame the DCF?

A sensible model separates operating cash flow from temporary working-capital and tax effects, estimates recurring capitalized software and infrastructure needs, and explicitly models stock-based compensation or the share dilution it creates. It should also distinguish interest income from operating income because the return on the liquidity portfolio will vary with rates and capital deployment. Terminal assumptions should reflect a mature vertical-software company, not indefinite mid-teens growth.

What is the key takeaway from Veeva Systems analysis?

Veeva matters because it has built a profitable, cash-rich industry cloud around some of the life-sciences sector’s most regulated and operationally important workflows. Its strongest evidence of durability is not one product: it is the combination of 1,552 customers, 84% subscription revenue in FY2026, an 87% subscription gross margin, a growing R&D and Quality franchise, and a platform that can connect content, data, applications, and agents.

The central question is whether Veeva can convert that installed base and domain expertise into a fully proprietary next-generation platform without losing too much CRM business during the transition. Vault CRM, Veeva AI, Ostro, and Falcon create a credible path to deeper workflow automation. At the same time, Salesforce competition, customer migration choices, security and compliance obligations, high stock-based compensation, and acquisition integration can weaken the outcome.